The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine Gardasil

Journal of Adolescent Health

Volumn 49, Issue 5, 2011, Pages 467-475

  Haupt, Richard M ^a   Sings, Heather L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gardasil; HPV; HPV vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANUS CANCER; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRECANCER; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; VACCINATION; VAGINA CANCER; VULVA CANCER;

ADOLESCENT; ADOLESCENT BEHAVIOR; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; SEX EDUCATION; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 80055018810     PISSN: 1054139X     EISSN: 18791972     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2011.07.003     Document Type: Review

References (117)

1. W. Bonnez Papillomavirus D.D. Richman, R.J. Whitley, F.G. Hayden, Clinical Virology 2nd ed 2002 ASM Press Washington, DC 557 596
2. M. Stanley Pathology and epidemiology of HPV infection in females Gynecol Oncol 117 2010 S5 S10
3. N. Muoz, F.X. Bosch, and S. de Sanjosé Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 2003 518 527 (Pubitemid 36159887)
4. N. Li, S. Franceschi, and R. Howell-Jones Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication Int J Cancer 128 2011 927 935
5. N. Muoz, X. Castellsague, A.B. de Gonzalez, and L. Gissmann HPV in the etiology of human cancer Vaccine 24 2006 S1 S10
6. J. Paavonen, P. Naud, and J. Salmerón Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women Lancet 374 2009 301 314
7. S.M. Garland, M. Hernandez-Avila, and C.M. Wheeler Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N Engl J Med 356 2007 1928 1943 (Pubitemid 46740303)
8. The FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 2007 1915 1927
9. N. Muoz, S.K. Kjaer, and K. Sigurdsson Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women J Natl Cancer Inst 102 2010 325 339
10. D.M. Parkin, and F. Bray The burden of HPV-related cancers Vaccine 24 Suppl 3 2006 S11 S25
11. G.M. Clifford, J.S. Smith, T. Aguado, and S. Franceschi Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis Br J Cancer 89 2003 101 105 (Pubitemid 36897943)
12. S. de Sanjose, W.G. Quint, and L. Alemany Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study Lancet Oncol 11 2010 1048 1056
13. J. Ferlay, F. Bray, P. Pisani GLOBOCAN Cancer incidence, mortality and prevalence worldwide IARC Cancer Base No. 5, Version 2.0 2002 IARC Press Lyon, France http://www-dep.iarc.fr/globocan/ Accessed May 2, 2011
14. M.A. Kane, J. Sherris, and P. Coursaget HPV vaccine use in the developing world Vaccine 24 Suppl 3 2006 S3/1329
15. M. Arbyn, A.O. Raifu, P. Autier, and J. Ferlay Burden of cervical cancer in Europe: Estimates for 2004 Ann Oncol 18 2007 1708 1715 (Pubitemid 47506260)
16. National Cancer Institute Cervical Cancer http://www.cancer.gov/ cancertopics/types/cervical Accessed May 2, 2011
17. X. Castellsagué, M. Díaz, and S. de Sanjosé Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention J Natl Cancer Inst 98 2006 303 314
18. S.S. Wang, M.E. Sherman, and A. Hildesheim Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 19762000 Cancer 100 2004 1035 1044 (Pubitemid 38232621)
19. M.E. Sherman, S.S. Wang, J. Carreon, and S.S. Devesa Mortality trends for cervical squamous and adenocarcinoma in the United States - Relation to incidence and survival Cancer 103 2005 1258 1264 (Pubitemid 40328098)
20. A.P. Vizcaino, V. Moreno, and F.X. Bosch International trends in the incidence of cervical cancer: I Adenocarcinoma and adenosquamous cell carcinomas Int J Cancer 75 1998 536 545 (Pubitemid 28094098)
21. S. Bulk, O. Visser, and L. Rozendaal Cervical cancer in the Netherlands 19891998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women Int J Cancer 113 2005 1005 1009 (Pubitemid 40096882)
22. International Agency for Research on Cancer Handbooks of Cancer Prevention Cervix Cancer Screening Vol 9 2004 IARC Press Lyon, France
23. M.P. Hopkins, and G.W. Morley A comparison of adenocarcinoma and squamous cell carcinoma of the cervix Obstet Gynecol 77 1991 912 917
24. G.M. Clifford, J.S. Smith, and M. Plummer Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis Br J Cancer 88 2003 63 73
25. N. Muoz, F.X. Bosch, and X. Castellsagué Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int J Cancer 111 2004 278 285 (Pubitemid 38924707)
26. D.G. Ferris, J.T. Cox, and D.M. O'Connor Modern Colposcopy, Textbook, and Atlas 2nd edition 2004 Kendall/Hunt Publishing Dubuque, IA
27. J.L. Benedet, H. Bender, and H. Jones FIGO Staging Classifications and Clinical Practice Guidelines in the management of gynecologic cancers FIGO Committee on gynecologic oncology Int J Gynecol Obstet 70 2000 209 262
28. J. Peto, C. Gilham, and J. Deacon Cervical HPV infection and neoplasia in a large population-based prospective study: The Manchester cohort Br J Cancer 91 2004 942 953 (Pubitemid 39273789)
29. ASCUS-LSIL Triage Study (ALTS) Group A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations Am J Obstet Gynecol 188 2003 1393 1400
30. ASCUS-LSIL Triage Study (ALTS) Group Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance Am J Obstet Gynecol 188 2003 1383 1392
31. American Cancer Society Detailed Guide: Cervical Cancer What Are the Key Statistics About Cervical Cancer? http://www.cancer.org/cancer/cervicalcancer/ detailedguide/cervical-cancer-key-statistics Accessed May 2, 2011
32. A.R. Giuliano, and D. Salmon The case for a gender-neutral (universal) human papillomavirus vaccination policy in the United States: Point Cancer Epidemiol Biomarkers Prev 17 2008 805 808
33. R.J. Kurman, D.E. Henson, and A.L. Herbst Interim guidelines for management of abnormal cervical cytology The 1992 National Cancer Institute Workshop JAMA 271 1994 1866 1869 (Pubitemid 24169702)
34. C.P. Morrow, and W. Cozen Perspective on cervical cancer: Why prevent? J Cell Biochem 23 Suppl 1995 61 70 (Pubitemid 26032859)
35. T. Linglöf, J. van Hattum, and K.M. Kaplan An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: Safety, tolerability, and immunogenicity Vaccine 19 2001 3968 3971 (Pubitemid 32566321)
36. R.P. Insinga, A.G. Glass, and B.B. Rush The health care costs of cervical human papillomavirus-related disease Am J Obstet Gynecol 191 2004 114 120 (Pubitemid 39077963)
37. G.M. Clifford, R.K. Rana, and S. Franceschi Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer Cancer Epidemiol Bios Prev 14 2005 1157 1164 (Pubitemid 40656461)
38. FUTURE II Study Group Four year efficacy of prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine against low-grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial BMJ 340 2010 c3493
39. S.K. Kjaer, K. Sigurdsson, and O.-E. Iversen A pooled analysis of continued prophylactic efficacy of quadrivalent HPV (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions Cancer Prev Res 2 2009 868 878
40. Merck & Co Gardasil prescribing information http://www.merck.com/ product/usa/pi-circulars/g/gardasil/gardasil-pi.pdf Accessed May 2, 2011
41. A.R. Giuliano, J.M. Palefsky, and S. Goldstone Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males N Engl J Med 364 2011 401 411
42. E.-M. de Villiers, C. Fauquet, and T.R. Broker Classification of papillomaviruses Virology 324 2004 17 27 (Pubitemid 38737395)
43. D.R. Brown, S.K. Kjaer, and K. Sigurdsson The Impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV naive women aged 1626 J Infect Dis 199 2009 926 935
44. H. De Vuyst, G.M. Clifford, and M.C. Nascimento Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis Int J Cancer 124 2009 1626 1636
45. American Cancer Society Detailed Guide: Anal Cancer What Are the Key Statistics About Anal Cancer? http://www.cancer.org/cancer/analcancer/ detailedguide/anal-cancer-what-is-key-statistics Accessed May 2, 2011
46. J.M. Palefsky Human papillomavirus-related disease in men: Not just a women's issue J Adolesc Health 46 2010 S12 S19
47. L.G. Johnson, M.M. Madeleine, and L.M. Newcomer Anal cancer incidence and survival: The surveillance, epidemiology, and end results experience, 19732000 Cancer 101 2004 281 288 (Pubitemid 38890830)
48. J.R. Daling, N.S. Weiss, and L.L. Klopfenstein Correlates of homosexual behavior and the incidence of anal cancer JAMA 247 1982 1988 1990 (Pubitemid 12133712)
49. J.R. Qualters, N.C. Lee, and R.A. Smith Breast and cervical cancer surveillance, United States, 19731987 MMWR CDC Surveill Summ 41 1992 1 7
50. E. Vardas, A.R. Giuliano, and Goldstone External genital HPV prevalence and associated factors among heterosexual men on five continents J Infect Dis 203 2011 58 65
51. S.E. Goldstone, J. Palefsky, and A. Giuliano Prevalence and risk factors for HPV infection in HIV serogenative men who have sex with men J Infect Dis 203 2010 66 74
52. S.E. Goldstone A case assignment methodology for determining quadrivalent HPV vaccine efficacy against AIN in men having sex with men26th Annual International Papillomavirus Conference and Clinical Workshop http://hpv2010.org/main/ Accessed May 2, 2011
53. R. Sankaranarayanan, and J. Ferlay Worldwide burden of gynaecological cancer: The size of the problem Best Pract Res Clin Obstet Gynaecol 20 2006 207 225 (Pubitemid 43380597)
54. P.L. Judson, E.B. Habermann, N.N. Baxter, S.B. Durham, and B.A. Virnig Trends in the incidence of invasive and in situ vulvar carcinoma Obstet Gynecol 107 2006 1018 1022
55. M. Hampl, S. Deckers-Figiel, and J.A. Hampl New aspects of vulvar cancer: Changes in localization and age of onset Gynecol Oncol 109 2008 340 345
56. E.A. Joura Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia Curr Opin Obstet Gynecol 14 2002 39 43 (Pubitemid 34177906)
57. Centers for Disease Control and Prevention HPV-Associated Vaginal Cancer Rates by Race and Ethnicity, 2010 http://www.cdc.gov/cancer/hpv/statistics/ vaginal.htm Accessed May 2, 2011
58. B. Winter-Roach, J. Monaghan, and A. de Lopes Colposcopy of the vagina P. Bosze, D. Luesley, EAGC Course Book on Colposcopy 2004 Primed-X Press Budapest, Hungary 120 123
59. P.M. Lenehan, F. Meffe, and G.M. Lickrish Vaginal intraepithelial neoplasia - Biologic aspects and management Obstet Gynecol 68 1986 333 337 (Pubitemid 16046492)
60. A. Schneider, E.M. de Villiers, and V. Schneider Multifocal squamous neoplasia of the female genital tract: significance of human papillomavirus infection of the vagina after hysterectomy Obstet Gynecol 70 1987 294 298 (Pubitemid 17151643)
61. American Society for Colposcopy and Cervical Pathology ASCCP practice recommendations: Practice management materials: The vagina http://www.asccp.org/ edu/practice/vagina/neoplasia.shtml Accessed May 2, 2011
62. M. Aho, E. Vesterinen, and B. Meyer Natural history of vaginal intraepithelial neoplasia Cancer 68 1991 195 197
63. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) Human papillomavirus and related cancers in United Kingdom Summary Report 2010 http://www.who.int/hpvcentre Accessed May 2, 2011
64. M. Hampl, H. Sarajuuri, and N. Wentzensen Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer Obstet Gynecol 108 2006 1361 1368 (Pubitemid 44901008)
65. B.J. Monk, R.A. Burger, and F. Lin Prognostic significance of human papillomavirus DNA in vulvar carcinoma Obstet Gynecol 85 1995 709 715
66. D. Hu, and S. Goldie The economic burden of noncervical human papillomavirus disease in the United States Am J Obstet Gynecol 198 2008 500 507
67. D.J. Wiley, J. Douglas, and K. Beutner External genital warts: Diagnosis, treatment and prevention Clin Infect Dis 35 2002 S210 S224 (Pubitemid 35178333)
68. K.U. Jansen, and A.R. Shaw Human papillomavirus vaccines and prevention of cervical cancer Annu Rev Med 55 2004 319 331 (Pubitemid 38316730)
69. S.M. Garland, M. Steben, and H.L. Sings Natural history of genital warts: Analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine J Infect Dis 199 2009 805 814
70. E.R. Myers The economic impact of HPV vaccines: Not just cervical cancer Am J Obstet Gynecol 198 2008 487 488 (Pubitemid 351609024)
71. A.B. Fleischer, C.A. Parrish, R. Glenn, and S.R. Feldman Condylomata acuminata (genital warts) - Patient demographics and treating physicians Sex Transm Dis 28 2001 643 647 (Pubitemid 33055108)
72. J.E. Koshiol, S.A. Laurent, J.M. Pimenta, and J.M. Pimenta Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States Sex Transm Dis 31 2004 748 752 (Pubitemid 39557423)
73. Health Protection Agency Focus on prevention: HIV and other sexually transmitted infections in the United Kingdom in 2003 - An update: November 2004 London, England, United Kingdom, 2004 http://www.hpa.org.uk/Publications/ InfectiousDiseases/HIVAndSTIs/0411FocusonPreventionHIVSTIsUK/ Accessed May 2, 2011
74. P. Clarke, C. Ebel, D.N. Catotti, and S. Stewart The psychosocial impact of human papillomavirus infection: Implications for health care providers Int J STD AIDS 7 1996 197 200 (Pubitemid 26191688)
75. R.D. Maw, M. Reitano, and M. Roy An international survey of patients with genital warts: Perceptions regarding treatment and impact on lifestyle Int J STD AIDS 9 1998 571 578 (Pubitemid 28474812)
76. R.P. Insinga, E.J. Dasbach, and E.R. Myers The health and economic burden of genital warts in a set of private health plans in the United States Clin Infect Dis 36 2003 1397 1403 (Pubitemid 36702873)
77. P.C. Langley, D.J. White, and S.M. Drake The costs of treating external genital warts in England and Wales: A treatment pattern analysis Int J STD AIDS 15 2004 501 508 (Pubitemid 39120231)
78. C.J. Lacey, C.M. Lowndes, and K.V. Shah Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease Vaccine 24 Suppl 3 2006 S35 S41 (Pubitemid 44293033)
79. M.C. Zacharisen, and S.F. Conley Recurrent respiratory papillomatosis in children: Masquerader of common respiratory diseases Pediatrics 118 2006 1925 1931 (Pubitemid 46393674)
80. S. Stamataki, T.P. Nikolopoulos, and S. Korres Juvenile recurrent respiratory papillomatosis: Still a mystery disease with difficult management Head Neck 29 2007 155 162 (Pubitemid 46167783)
81. G.L. Freed, and C.S. Derkay Prevention of recurrent respiratory papillomatosis: Role of HPV vaccination Int J Pediatr Otorhinolaryngol 70 2006 1799 1803 (Pubitemid 44291452)
82. B.Y. Hernandez, J. Barnholtz-Sloan, and R.R. German Burden of invasive squamous cell carcinoma of the penis in the United States, 19982003 Cancer 113 2008 2883 2891
83. M.A. Rubin, B. Kleter, and M. Zhou Detection and typing of human papillomavirus DNA in penile carcinoma: Evidence for multiple independent pathways of penile carcinogenesis Am J Pathol 159 2001 1211 1218 (Pubitemid 32947950)
84. C. Miralles-Guri, L. Bruni, and A.L. Cubilla Human papillomavirus prevalence and type distribution in penile carcinoma J Clin Pathol 62 2009 870 878
85. C.C.R. Ragin, F. Modugno, and S.M. Gollin The epidemiology and risk factors of head and neck cancer: A focus on human papillomavirus J Dent Res 86 2007 104 114
86. C.H. Chung, and M.L. Gillison Human papillomavirus in head and neck cancer: Its role in pathogenesis and clinical implications Clin Cancer Res 15 2009 6758 6762
87. H. Mehanna, T.M. Jones, V. Gregoire, and K.K. Ang Oropharyngeal carcinoma related to human papillomavirus BMJ 340 2010 c1439
88. A.R. Kreimer, G.M. Clifford, and P. Boyle Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review Cancer Epidemiol Bios Prev 14 2005 467 475 (Pubitemid 40270113)
89. S. Syrjnen, G. Lodi, and I. von Bltzingslöwen Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: A systematic review Oral Dis 17 Suppl 1 2011 58 72
90. M. Stanley Prophylactic HPV vaccines: Prospects for eliminating ano-genital cancer Br J Cancer 96 2007 1320 1323 (Pubitemid 46685776)
91. L.L. Villa, K.A. Ault, and A.R. Giuliano Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18 Vaccine 24 2006 5571 5583 (Pubitemid 44172918)
92. A.R. Giuliano, E. Lazcano-Ponce, and L. Villa Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine J Infect Dis 196 2007 1153 1162 (Pubitemid 47580270)
93. D. Opalka, C.E. Lachman, and S.A. MacMullen Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay Clin Diagn Lab Immunol 10 2003 108 115 (Pubitemid 36133838)
94. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil(R) over four years as defined by total IgG and competitive luminex immunoassay. Hum Vaccin (in press).
95. M. Nakagawa, R. Viscidi, and I. Deshmukh Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women Clin Diagn Lab Immunol 9 2002 877 882 (Pubitemid 34773894)
96. S.-E. Olsson, L.L. Villa, and R.L. Costa Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18L1 virus-like-particle vaccine Vaccine 25 2007 4931 4939 (Pubitemid 46843434)
97. L.L. Villa, R.L.R. Costa, and C.A. Petta High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18L1 virus-like particle vaccine through 5 years of follow-up Br J Cancer 95 2006 1459 1466 (Pubitemid 44863348)
98. S.-E. Olsson, S.K. Kjaer, and K. Sigurdsson Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection Hum Vaccin 5 2009 696 704
99. S.L. Block, T. Nolan, and C. Sattler Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women Pediatrics 118 2006 2135 2145 (Pubitemid 46393698)
100. CDC Factsheet: Meningococcal diseases and meningococcal vaccines http://www.cdc.gov/vaccines/vpd-vac/mening/vac-mening-fs.htm 2009 Accessed May 2, 2011
101. K.R. Broder, M.M. Cortese, and J.K. Iskander Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices, Healthcare Infection Control Practices Advisory Committee MMWR Recomm Rep 55 2006 1 34
102. Centers for Disease Control and Prevention Adolescent Immunization What Is the Public Health Issue? http://www.cdc.gov/NCIRD/progbriefs/downloads/ adolescent.pdf 2007 Accessed May 2, 2011
103. Centers for Disease Control and Prevention National, state, and local area vaccination coverage among adolescents aged 1317 years United States, 2009 MMWR Recomm Rep 59 2010 1018 1021
104. K.S. Reisinger, S.L. Block, and M. Collins-Ogle Safety, tolerability, and immunogenicity of Gardasil given concomitantly with menactra and adacel Pediatrics 125 2010 1142 1151
105. C.M. Wheeler, O.M. Bautista, and J.E. Tomassini Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines Vaccine 26 2008 686 696
106. S.L. Block, D.R. Brown, and A. Chatterjee Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6; 11, 16, and 18) l1 virus-like particle vaccine Pediatr Infect Dis J 29 2009 95 101
107. A.T. Kroger General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 55 2006 1 48
108. B.A. Slade, L. Leidel, and C. Vellozzi Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine JAMA 302 2009 750 757
109. Centers for Disease Control and Prevention Summary of HPV Adverse Event Reports Published in JAMA CDC website, 2009 http://www.cdc.gov/vaccinesafety/ Vaccines/HPV/jama.html Accessed May 2, 2011
110. T. Agorastos, K. Chatzigeorgiou, J.M. Brotherton, and S.M. Garland Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far Vaccine 27 2009 7270 7281
111. L.E. Markowitz, S. Hariri, and E.R. Unger Post-licensure monitoring of HPV vaccine in the United States Vaccine 28 2010 4731 4737
112. P. Bonanni, C. Cohet, and S.K. Kjaer A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD(R) Vaccine 28 2010 4719 4730
113. J.M.L. Brotherton, S.L. Deeks, and S. Campbell-Lloyd Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia Commun Dis Intell 32 2008 457 461
114. C.K. Fairley, J.S. Hocking, and L.C. Gurrin Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women Sex Transm Infect 85 2009 499 502
115. B. Donovan, N. Franklin, and R. Guy Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: Analysis of National Sentinel Surveillance Data Lancet 11 2011 39 44
116. J. Brotherton, M. Fridman, and M. Saville First indication of a possible impact on cervical abnormalities following a national HPV vaccination program, in Victoria, Australia, 2010 http://hpv2010.org/mwg-internal/de5fs23hu73ds/ progress?id=RKGuErfdN1 Accessed May 2, 2011
117. G.D. Zimet, and S.L. Rosenthal HPV vaccine and males: Issues and challenges Gynecol Oncol 117 2010 S26 S31